Redesign Health develops technologies, tools, and insights to solve healthcare solutions.
Redesign Health develops technologies, tools, and insights to solve healthcare solutions.
Enterprise Systems (Healthcare)📍 San Francisco, CAFounded 2024
Current Valuation
$1.6B
as of 2022-Q3
UNICORN
QL Price
$901.66M
-44% vs last round
QuantLogix's current estimate for Redesign Health, published 2026-09-27 — below the last disclosed round of $1.6B (2022-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.6B
2022-Q3
weight 0.06
Secondary market print
$825.6M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Redesign Health since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Redesign Health, 2026-09-27 (39501a05a9ece727).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Redesign Health going public?
No. Redesign Health is private and has not filed to go public. There is no S-1 on file.
What is Redesign Health's valuation in 2026?
Redesign Health is valued at $1.6B as of 2022-Q3, set by its Series C ($65M, Sep 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Redesign Health filed an S-1?
No public S-1 is on file for Redesign Health.
How much has Redesign Health raised?
Redesign Health has raised $201M in total, most recently a Series C of $65M in Sep 2022.
Is Redesign Health publicly traded — can you buy Redesign Health stock?
No. Redesign Health is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Redesign Health on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2024
HQ
San Francisco, CA
Employees
7
Total Raised
$201M
Last Round
Series C — $65M (Sep 2022)
IPO Status
private
Fundraising Status
Series C · $65M · 4y ago
privateTotal raised $201M
Secondary Market
Implied price / share
$8.72
Last round price / share
$16.89
vs last round
-48.4%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$65M
Sep 2022
—
$1.6B
Talent Signal
Hiring trend
▼ Hiring downtrend
-50% vs 2026-08
Open roles
1
via ashby
Product-build share
0%
engineering, research, product, design
Trajectory
tightening
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 1 open roles are sales).
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
VP, Sales
Counted from Redesign Health's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health Care
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q3. Refreshed quarterly.